Kolexia
Andre Thierry Oncologie médicale
Andre Thierry
Oncologie médicale
Hôpital Saint-Antoine
Paris, France
705 Activités
604 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs colorectales Tumeurs du côlon Instabilité des microsatellites Adénocarcinome Métastase tumorale Carcinomes Tumeurs du rectum Récidive tumorale locale Tumeurs du pancréas

Collaborateurs

Voir plus
Taieb Julien
Taieb Julien
Hôpital Européen Georges Pompidou, Paris, France
Cohen Romain
Cohen Romain
Hôpital Saint-Antoine, Paris, France
Louvet Christophe
Louvet Christophe
Institut Mutualiste Montsouris, Paris, France
Tournigand Christophe
Tournigand Christophe
Hôpital Henri Mondor, Créteil, France

Industries

Voir plus
Servier
24 collaboration(s)
Dernière en 2023
MSD
20 collaboration(s)
Dernière en 2023
Amgen
14 collaboration(s)
Dernière en 2022
GSK
12 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008): A Phase 2, Multicenter, Multi Arm, Study to Evaluate MK-1308A (Co-formulated Quavonlimab (MK-1308)/Pembrolizumab) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer: (MK-1308A-008)
Essai Clinique (Merck & Co.)   20 mars 2024
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer: AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E-MUTANT COLORECTAL CANCER
Essai Clinique (Pfizer)   17 mars 2024
MOUNTAINEER-03: An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer
Essai Clinique (Seagen)   15 mars 2024
SCARCE: A Non-comparative Randomized 2:1 Phase II Study of Docetaxel, Cisplatin, and 5-fluorouracil in Combination or Not With Atezolizumab in Patients With Metastatic or Unresectable Locally Advanced Squamous Cell Anal Carcinoma
Essai Clinique (Roche)   08 mars 2024
STRATEGIC-1: Multi-Line Therapy Trial in Unresectable Wild-Type RAS Metastatic Colorectal Cancer. A GERCOR Randomized Open-label Phase III Study.
Essai Clinique (Roche)   08 mars 2024
iintune-1: An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
Essai Clinique (Takeda Pharmaceutical)   07 mars 2024
Comparative efficacy of PD-1 blockade in patients with dMMR/MSI-H metastatic colorectal or gastric cancer: a global retrospective study
ESMO Gastrointestinal Oncology   01 mars 2024
DEWI: Watch-and-wait Strategy to Initiate Dostarlimab-based Immunotherapy in Localized Deficient Mismatch Repair (dMMR) and/or Microsatellite Instability High (MSI-H) oEso-gastric Junction and Gastric Adenocarcinoma: An Open-label GERCOR Phase II Study
Essai Clinique (GERCOR (Multidisciplinary Group in Oncology))   02 février 2024
7P Molecular targeted therapies based on metastatic site in first-line treatment for colorectal cancer patients: An ARCAD pooled analysis
Abstract Book of the ESMO Targeted Anticancer Therapies Congress (TAT) 26 - 28 February 2024   01 février 2024
ANCHOR-CRC: Phase II, Open-label, Single Arm, Multicenter Study of Encorafenib, Binimetinib Plus Cetuximab in Subjects With Previously Untreated BRAF V600E -Mutant Metastatic Colorectal Cancer
Essai Clinique (Pierre Fabre)   31 janvier 2024